Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

24-hour diastolic ambulatory blood pressure and mean seated office systolic and diastolic blood pressure as well as a number of other endpoints.

Investor event at ASH

Pharmacopeia will host a meeting for investors today, Friday, May 16th at 7:00am CDT (8:00am EDT) to review the Phase 2a study results from its PS433540 program, including a presentation by Joel Neutel, M.D., the study's lead investigator. A live webcast and 90-day archive of the presentation can be accessed on the Investors section of the company's website at http://www.pharmacopeia.com.

About PS433540

PS433540 is the first and only blood pressure product candidate in a new class of antihypertensives known as Dual Acting Receptor Antagonists (DARAs). PS433540 is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540 possesses two clinically validated mechanisms of action in a single molecule. There is preclinical and initial clinical data suggesting that compared to either mechanism alone, simultaneously blocking angiotensin II and endothelin 1 at their respective receptors, AT1 and ETA, may provide an improved treatment option for several cardiovascular diseases. Because PS433540 is highly selective for the AT1 and ETA receptors it is able to block the blood pressure-raising actions of angiotensin and endothelin when they bind to these receptors.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The compa
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... 27, 2015 According to a new market ... Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type ... published by MarketsandMarkets, the Medical Lifting Sling Market is poised to ... 2015, at a CAGR of 11.4 % from 2015 to 2020. ... rket data T ables and 65 ...
(Date:8/27/2015)... 27, 2015  Now that Intuitive Surgical, Inc.® has ... surgical robot, hospitals with robotic surgery programs need to ... to see where they stand with robotic surgery. Are ... Have they adopted best practices for safety? Should they ... future? ECRI Institute, which has nearly 50 ...
Breaking Medicine Technology:Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... advantage of five major benefits of the new health care law, ... To help you better understand the Affordable Care Act, ... , a web portal that explains what,s changing and when. ... is Mayra Alvarez, Director of Public Health Policy in the Office ...
... 2011 Echo Therapeutics, Inc. (OTCBB: ... as a non-invasive, wireless, transdermal continuous glucose monitoring ... transdermal drug delivery, today announced that Christopher P. ... Financial Officer.  Mr. Schnittker is a senior executive ...
Cached Medicine Technology:Five Benefits of the New Health Care Law 2Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer 2Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer 3
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis ... information technology innovation to transform quality and efficiency of healthcare delivery worldwide, announced ... de-identified and aggregated before being publicly shared to document progress and inform policy ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... organization, is pleased to welcome TJS Insurance Group as its newest Partner Firm. ... clients guides them and keeps them focused on their goals. Within the past ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Plaintiffs Steering ... MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in the midst of ... files the PSC may receive for corporate employees involved in the production or ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... will run a half-marathon here Monday in his bid to complete ... raise 100,000 pounds for cancer// research. ,"The 'Great World ... Young, 32, plans to run 314.4 miles between Sep 7 and ... of his endeavour. His final run will be at Newcastle upon ...
... to take stock of the growing numbers of people with ... to The Access// Economics report, Asia Pacific Region. ... Asia Pacific region may see a rise in the condition ... region will have to contend with nearly 19.7 million cases, ...
... A national survey has revealed that 26% of teenagers have ... study was conducted by Guideline Inc. on behalf of Liberty ... with drivers' licenses at 26 high schools nationwide. ... during homeroom or study hall to the teens. ...
... surgical ward floor in a Scottish hospital. The patients were ... in Elgin.// ,According to pest control experts, a ... infestation.,NHS Grampian said that the ward was thoroughly cleaned and ... ,An NHS Grampian spokesman said: "There was no ...
... are mere actors, echoed The Bard, eons ago. As the ... crippling disease, today on// World Alzheimer’s day, the stage is set ... its horns and evolve better strategies for effective management of the ... the central nervous system marked by stark and untimely backslide in ...
... Exotic treatments such as a soothing guilt-free chocolate body wrap ... of in post-communist Poland// just a few years ago. ... the growing Polish middle and chattering classes, who seek a ... ,"I received a present to spend a few ...
Cached Medicine News:Health News:World Alzheimer’s Day: In Memory of Those With 'Memory Loss 2Health News:World Alzheimer’s Day: In Memory of Those With 'Memory Loss 3Health News:Luxury Spas Ride Boom in Wellness Industry in Poland 2
... The introduction of the AMO ... in Phaco technology; The combination of ... in complete control of fluidic conditions ... as the "smart Pump" orchestrates the ...
... The Catalyst system introduces a ... precision to microsurgical instrumentation. It ... digital design with advanced microcomputer ... simple to operate with a ...
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Compact ultrasonic phacoemulsification system....
Medicine Products: